Andrade Robert 4

What Happened Robert Andrade, Chief Financial Officer of Fennec Pharmaceuticals (FENC), received 1,703 shares on June 30, 2026. The Form 4 shows an acquisition at $0.00 per share, indicating these were shares released from restrictions (not a purchased open-market transaction).

Key Details

• Transaction date: 2026-06-30; Form 4 filed: 2026-07-01 (timely).
• Transaction type: Award/Release of restricted shares (code A); price reported $0.00.
• Shares involved: 1,703 shares.
• Shares owned after transaction: not disclosed in the provided filing.
• Footnote F1: “Represents shares released from restriction from shares awarded 5/16/2024 and 3/28/2025.”
• No indication this was a sale, 10b5-1 plan, or tax-withholding disposition in the filing.

Context This was a routine compensation-related release of previously awarded restricted stock — common for executives as awards vest. Because the shares were released (not purchased), the transaction does not necessarily signal a buy or sell view by the insider. Such releases can have tax implications but are not an indicator of market sentiment by themselves.